How to appeal a CareFirst BCBS specialty biologics denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for specialty biologics

Cited policy: Anthem/Elevance Clinical UM Guideline clinical guideline - Adalimumab and Biosimilars

Moderate-severe disease + conventional therapy failure + TB/Hep B/C screening. Most BCBS plans now require biosimilar adalimumab first (2024-2026 adoption wave).

How CareFirst BCBS denies specialty biologics — and how to counter it

Where CareFirst BCBS pushes back: 1) Drug non-formulary; 2) Step therapy: failure of two preferred TNFi biosimilars required; 3) Lab work older than 12 months; 4) Missing rheumatologist/dermatologist/gastroenterologist attestation.

Counter-arguments that hold up: Identify the specific BCBS subsidiary and cite its named policy by number — generic appeals are weaker. For BCBS FEP: governed by FEHB; appeals to OPM after internal exhaustion (5 CFR 890.105). State external review under NAIC Model Act timelines. For self-funded ERISA BCBS plans: demand full claim file under 29 CFR 2560.503-1(h)(2)(iii).

What CareFirst BCBS typically denies for specialty biologics

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For specialty biologics, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the specialty biologics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Stelara
• Skyrizi
• Cosentyx

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.